ClinicalTrials.gg
RecruitingNCT07306754Updated Jan 12, 2026

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.

A Phase 1 interventional study of ABBV-243 and Placebo in Healthy Volunteers, sponsored by AbbVie. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The objective of this study is to assess the safety, tolerability, pharmacokinetics and immunogenicity of either single ascending intravenous (IV) doses of ABBV-243 or single ascending subcutaneous (SC) doses of ABBV-243 in healthy adult participants (Part 1), and a single intravenous (IV) dose in healthy Asian adult volunteers (Part 2

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals between 18 and 60 years of age inclusive at the time of Screening.
  • is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth's decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • Females, Non- are eligible as defined by meeting the following criteria:

    • Permanent sterility due to a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
    • Non-surgical permanent infertility due to Mullerian agenesis, androgen insensitivity, or gonadal dysgenesis; investigator discretion should be applied to determining study entry.
    • female who is age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND an FSH level ≥ 30 IU/L.
    • Postmenopausal female who is age > 55 years with no menses for 12 or more months without an alternative medical cause.
  • Females, Childbearing Potential are defined as all other females who do not meet the above criteria and must adhere to the following:

    • Must not be pregnant or breastfeeding.
    • Must agree to avoid pregnancy while taking study treatment(s) and for at least 200 days after the last dose of study treatment.
    • Must agree to use a method listed below (as per local regulations) that is highly effective (with a failure rate of \< 1% per year, when used consistently and correctly). Participants must provide documentation to the site.
    • Bilateral tubal occlusion/ligation.
    • Intrauterine device (IUD) to be inserted at least 30 days prior to Screening.
    • Intrauterine hormone-releasing system (IUS) to be inserted at least 30 days prior to Screening.
  • Part 2 only:

Healthy Japanese and Han Chinese male or female; between 18 and 60 years of age, inclusive at the time of Screening.

- Han Chinese participants must be first- or second-generation Han Chinese of full Chinese parentage. First-generation participants are defined as those born in China to two parents and four grandparents also born in China of full Chinese descent. Second-generation participants are defined as those born outside of China to two parents and four grandparents born in China of full Chinese descent.

OR

- Japanese participants must be first- or second-generation Japanese of full Japanese parentage. First-generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent. Second-generation subjects born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent.

Exclusion criteria

Exclusion Criteria:

  • History: of epilepsy, any cardiovascular, respiratory (except mild asthma as a child), renal, endocrine, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • Evidence of dysplasia or history of (including lymphoma and leukemia) other than successfully treated non- cutaneous squamous cell, basal cell carcinoma, or localized carcinoma in situ of the cervix.
  • History or evidence of active Tuberculosis (TB) disease or latent TB infection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Group 1: ABBV-243 or Placebo

    Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1

    Drug: ABBV-243 · Drug: Placebo

  • Experimental
    Group 2: ABBV-243 or Placebo

    Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1

    Drug: ABBV-243 · Drug: Placebo

  • Experimental
    Group 3: ABBV-243 or Placebo

    Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1

    Drug: ABBV-243 · Drug: Placebo

  • Experimental
    Group 4: ABBV-243 or Placebo

    Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1

    Drug: ABBV-243 · Drug: Placebo

  • Experimental
    Group 5: ABBV-243 or Placebo

    Participants will receive either a single subcutaneous (SC) dose of ABBV-243, or the placebo equivalent, on Day 1

    Drug: ABBV-243 · Drug: Placebo

  • Experimental
    Group 6: ABBV-243 or Placebo

    Participants will receive either a single subcutaneous (SC) dose of ABBV-243, or the placebo equivalent, on Day 1

    Drug: ABBV-243 · Drug: Placebo

  • Experimental
    Group 7: ABBV-243 or Placebo

    Han Chinese participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1

    Drug: ABBV-243 · Drug: Placebo

  • Experimental
    Group 8: ABBV-243 or Placebo

    Japanese participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1

    Drug: ABBV-243 · Drug: Placebo

Interventions

  • DrugABBV-243

    Intravenous (IV) Infusion

  • DrugPlacebo

    Intravenous (IV) Infusion

  • DrugABBV-243

    Subcutaneous (SC) Injection

  • DrugPlacebo

    Subcutaneous (SC) Injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Day 204

  2. Maximum Observed Serum Concentration (Cmax) of ABBV-243

    Maximum observed serum concentration (Cmax) of ABBV-243

    Time frame: Up to Day 204

  3. Time to Cmax (Tmax) of ABBV-243

    Time to Cmax (Tmax) of ABBV-243

    Time frame: Up to Day 204

  4. Area Under the Serum Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-243

    Area under the serum concentration-time curve (AUC) from time 0 to the time of last measurable concentration (AUCt) of ABBV-243

    Time frame: Up to Day 204

  5. Area Under the Serum Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-243

    AUC from time 0 to infinite time (AUCinf) of ABBV-243

    Time frame: Up to Day 204

  6. Terminal Phase Elimination Rate Constant (β) of ABBV-243

    Terminal phase elimination rate constant of ABBV-243

    Time frame: Up to Day 204

  7. Terminal Phase Elimination Half-Life (t1/2) of ABBV-243

    Terminal phase elimination half-life of ABBV-243

    Time frame: Up to Day 204

  8. Anti-Drug Antibody (ADA) of ABBV-243

    Confirmed Positive ADA Results.

    Time frame: Up to Day 204

07

Study locations

1 of 1 sites recruiting
  • Acpru /Id# 279789
    Grayslake, Illinois 60030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 29, 2025
StartActual
Dec 17, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07306754
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Dec 17, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jan 12, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion